Headquartered in Perth, Western Australia, OncoRes Medical is a medical device company focused on eliminating repeat operations after breast-conserving surgery. Its core product, Elora™, uses Quantitative Micro-Elastography (QME) to provide surgeons with real-time, high-resolution mechanical and optical maps of tissue stiffness inside the surgical cavity, enabling more complete tumour removal. The device received FDA Breakthrough Device Designation in 2020, positioning it for an expedited U.S. regulatory pathway. The company has launched an Australian multi-site clinical trial that will enroll more than 110 patients to generate interventional data. Capital from the latest raise will fund this trial, advance product development, support manufacturing for a U.S. pivotal trial, and expand the team. OncoRes also plans to explore additional cancer indications such as prostate cancer. Medtech veteran Renee Ryan recently joined the board to guide U.S. market entry and long-term commercialization.

Total raised

$132M

Funding rounds

4

Latest round

Equity

Latest activity

Feb 2026